Cargando…

A Comparison of Chemotherapy Used with and without Apatinib for Patients with Ovarian Carcinoma Who Progressed after Standard Regimens: A Systematic Review and Meta-Analysis

OBJECTIVE: This meta-analysis was conducted to compare the therapeutic efficacy and clinical safety of the combination therapy of apatinib plus chemotherapy with that of chemotherapy alone in patients with refractory or recurrent ovarian carcinoma (OC). METHODS: Relevant randomized controlled trials...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hou, Chao, Jiang, Zhuang-Zhuang, Pan, Bo, Zhang, Xiao-Chun, Liu, Yan-Qing
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2021
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8580656/ https://www.ncbi.nlm.nih.gov/pubmed/34777533 http://dx.doi.org/10.1155/2021/2292907

Ejemplares similares

A Study Of Efficacy And Safety With Apatinib Or Apatinib Combined With Chemotherapy In Recurrent/advanced Ovarian Cancer Patients
por: Yang, Mi, et al.
Publicado: (2019)

Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC
por: Zhou, Peng-zhe, et al.
Publicado: (2021)

Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report
por: Zhang, Mingzi, et al.
Publicado: (2017)

Apatinib treatment combined with chemotherapy for advanced epithelial ovarian cancer: a case report
por: Deng, Linghui, et al.
Publicado: (2017)

Apatinib treatment efficiently delays biochemical-only recurrent ovarian cancer progression
por: Wang, Zhongyu, et al.
Publicado: (2021)

Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
por: Chen, Jianzhao, et al.
Publicado: (2021)

Progress in the treatment of solid tumors with apatinib: a systematic review
por: Zhao, Deze, et al.
Publicado: (2018)

Response to apatinib in chemotherapy-failed advanced spindle cell breast carcinoma
por: Zhou, Na, et al.
Publicado: (2016)

Apatinib in treating patients with recurrent or metastatic nasopharyngeal carcinoma who had failed prior platinum-based chemotherapy
por: Tao, Chang-Juan, et al.
Publicado: (2020)

Retracted: Efficacy, Safety, and Tumor Marker Inhibition of Apatinib Combined with Conventional Chemotherapy Regimens for Patients with Advanced Triple-Negative Breast Cancer
por: and Alternative Medicine, Evidence-Based Complementary
Publicado: (2023)

Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study
por: Guo, Yesong, et al.
Publicado: (2019)

Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment
por: Bai, Ming, et al.
Publicado: (2021)

Apatinib combined with SOX regimen for conversion therapy in advanced gastric cancer patients: a retrospective cohort study
por: Deng, Ya-Ya, et al.
Publicado: (2023)

Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer
por: Pan, Zhongmian, et al.
Publicado: (2023)

Neoadjuvant PD-1 Inhibitor Plus Apatinib and Chemotherapy Versus Apatinib Plus Chemotherapy in Treating Patients With Locally Advanced Gastric Cancer: A Prospective, Cohort Study
por: Wang, Chunjing, et al.
Publicado: (2023)

Apatinib Plus Chemotherapy Shows Clinical Activity in Advanced NSCLC: A Retrospective Study
por: Tang, Jing, et al.
Publicado: (2019)

Apatinib combined with chemotherapy in patients with previously treated advanced breast cancer: An observational study
por: Zhu, Anjie, et al.
Publicado: (2019)

Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma
por: Chen, Shiguang, et al.
Publicado: (2018)

Experimental study of the vascular normalization window for tumors treated with apatinib and the efficacy of sequential chemotherapy with apatinib in lung cancer‐bearing mice and patients
por: Liu, Mingtao, et al.
Publicado: (2020)

Clinical study of apatinib in the treatment of stage IV osteogenic sarcoma after failure of chemotherapy
por: Liao, Zhichao, et al.
Publicado: (2020)

A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer
por: Jiang, Xi-Ping, et al.
Publicado: (2016)

Phase III Trials of Standard Chemotherapy with or without Bevacizumab for Ovarian Cancer: A Meta-Analysis
por: Zhou, Mingyi, et al.
Publicado: (2013)

Efficacy of the Low Dose Apatinib plus Chemotherapy on Advanced Gastric Carcinoma
por: Gao, Shen, et al.
Publicado: (2022)

Efficacy, safety and pharmacokinetics of apatinib plus etoposide versus apatinib alone for platinum-resistant recurrent ovarian cancer: protocol of a multicenter, open-label, randomized phase 2 trial
por: Hou, Zhiguo, et al.
Publicado: (2023)

Activity and safety of apatinib monotherapy or apatinib combined with chemotherapy for patients with metastatic or unresectable osteosarcoma over the age of 40 years: A retrospective analysis
por: Gong, Taojun, et al.
Publicado: (2022)

Efficacy and Safety of Anlotinib for Patients with Advanced NSCLC Who Progressed After Standard Regimens and the Preliminary Analysis of an Efficacy Predictor
por: Cheng, Jian-De, et al.
Publicado: (2020)

Long-term progression-free survival of apatinib monotherapy for relapsed ovarian cancer: a case report and literature review
por: Zhang, Di, et al.
Publicado: (2019)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Comparison of first-line chemotherapy regimens for ovarian carcinosarcoma: a single institution case series and review of the literature
por: Brackmann, Melissa, et al.
Publicado: (2018)

Apatinib for treating advanced intrahepatic cholangiocarcinoma after failed chemotherapy: A case report and literature review
por: Wang, Li-Ye, et al.
Publicado: (2018)

Apatinib for recurrent/progressive glioblastoma multiforme: A salvage option
por: Zhang, Hong-Hong, et al.
Publicado: (2022)

Application effect of apatinib in patients with failure of standard treatment for advanced malignant tumours
por: Liu, Guohui, et al.
Publicado: (2019)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Apatinib plus chemotherapy for non-metastatic osteosarcoma: a retrospective cohort study
por: Wang, Jiaqiang, et al.
Publicado: (2023)

Hyperthermic Intraperitoneal Chemotherapy plus Intravenous Chemotherapy of Paclitaxel with or without Sintilimab in Gastric Cancer: A Comparative Study
por: Zhang, Zao, et al.
Publicado: (2022)

Use of apatinib combined with pemetrexed for advanced ovarian cancer: A case report
por: Sun, Huiting, et al.
Publicado: (2018)

Safety Analysis of Apatinib Combined with Chemotherapy in the Treatment of Advanced Gastric Carcinoma: A Randomised Controlled Trial
por: Yuan, Min, et al.
Publicado: (2021)

Clinical Outcomes and Safety of Apatinib Mesylate in the Treatment of Advanced Non-Squamous Non-Small Cell Lung Cancer in Patients Who Progressed After Standard Therapy and Analysis of the KDR Gene Polymorphism
por: Song, Zi-Zheng, et al.
Publicado: (2020)

A Modified Intraperitoneal Chemotherapy Regimen for Ovarian Cancer: Technique and Treatment Outcomes
por: Kim, Ji Hyun, et al.
Publicado: (2021)

Standardizing Chemotherapy Regimen Nomenclature: A Proposal and Evaluation of the HemOnc and National Cancer Institute Thesaurus Regimen Content
por: Rubinstein, Samuel M., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3k2eti2igjmerflvdctt02foh4